- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02613858
Minimal HePatic Encephalopathy Among CiRrhotics. A Cross SEctional, Clinico-EpidEmiological, Multi-Centre, Study in Patients of PakisTan (Preempt)
May 10, 2017 updated by: Abbott
The Preempt study is likely to help determine the frequency of patients suffering from Minimal Hepatic Encephalopathy (MHE) and are cirrhotics.
It will also enable us to know about the Quality of life of these patients.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
550
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Karachi, Pakistan, 74700
- Baqai Hospital
-
Lahore, Pakistan, 54000
- Fatima Memorial Hospital
-
Lahore, Pakistan, 54000
- Lahore general hospital
-
Lahore, Pakistan, 54550
- Jinnah Hospital Lahore
-
Lahore, Pakistan, 54770
- Doctor's Hospital
-
Peshawar, Pakistan, 25000
- Lady Reading hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Primary Care Clinic/Private Clinic
Description
Inclusion Criteria:
- Patients of either sex, 18-65 years of age, who have attended school at least till the 5th Class/Standard having an established diagnosis of liver cirrhosis without any overt symptoms at time of testing with Grade 0 of West Haven criteria.
- Patients willing to undergo the neuropsychological (NP) tests and to complete the SF-36 questionnaire for the estimation of Health Related Quality of Life (HRQOL).
- Patients willing to provide written authorization to provide data for the study.
Exclusion Criteria:
- Patients with inability to perform neuropsychometric tests and to complete the SF-36 questionnaire as decided by the physician.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of MHE in Cirrhotic patients
Time Frame: 18 months
|
Continuous variables with normal and non-normal distributions would be reported as mean (SD) and median [inter-quartile range (IQR)], respectively.
Prevalence of MHE in cirrhotic patients with 95% confidence Interval (CI) will be calculated.
Continuous variables between group will compared by using Independent sample t test, and categorical variables will compare by using the chi-square test.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The predisposing factors that might be associated with MHE in all enrolled patients with cirrhosis
Time Frame: 18 months
|
Odds Ratios (OR) and their 95% Confidence Intervals (CI) will be estimated using Logistic Regression.
The likelihood ratio test used to assess the association between the explanatory variables and the risk of the MHE.
Invariable analyses will perform to examine the effect of each variable on the risk of MHE.
In multivariate analysis all insignificant variables (p >0.05) will check for their confounding and interaction effects before their removal from the final model.
|
18 months
|
Quality of Life (QoL) of patients at baselines
Time Frame: 18 months
|
Short Form (SF)-36v2 Quality of Life Questionnaire will be used
|
18 months
|
Management of MHE currently in practice
Time Frame: 18 months
|
As per practice of the physician/Investigator.
Management of MHE will be recorded.
The information for medication which will be collected will be Name (preferably the generic name), Dose, Units (form of the medicine), Route and Frequency
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Raeefuddin Ahmed, MD, Medical Director, Abbott
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2015
Primary Completion (Actual)
March 1, 2017
Study Completion (Actual)
May 1, 2017
Study Registration Dates
First Submitted
November 6, 2015
First Submitted That Met QC Criteria
November 23, 2015
First Posted (Estimate)
November 25, 2015
Study Record Updates
Last Update Posted (Actual)
May 11, 2017
Last Update Submitted That Met QC Criteria
May 10, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPIDI038
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Encephalopathy
-
Jinnah Postgraduate Medical CentreNot yet recruitingHepatic Encephalopathy Stage 2 | Hepatic Encephalopathy Stage 3 | Hepatic Encephalopathy Stage 4Pakistan
-
Sherief Abd-ElsalamTanta UniversityUnknownEncephalopathy, HepaticEgypt
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterInstituto Grifols, S.A.; McGuire Research InstituteCompletedHepatic Encephalopathy | Cirrhosis | Minimal Hepatic Encephalopathy | Covert Hepatic EncephalopathyUnited States
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnRefractory Hepatic EncephalopathyIndia
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Aga Khan UniversityUnknownEncephalopathy, Hepatic | Hepatocerebral Encephalopathy | Portal-Systemic Encephalopathy | Encephalopathy, HepatocerebralPakistan
-
Consorci Sanitari de l'Alt Penedès i GarrafWithdrawn
-
Ain Shams UniversityCompletedMinimal Hepatic Encephalopathy
-
Mansoura UniversityCompletedMinimal Hepatic EncephalopathyEgypt
-
Shanghai Changzheng HospitalEnrolling by invitationHepatic Encephalopathy | Covert Hepatic EncephalopathyChina